Grupo para la caracterización molecular de las neoplasias hematológicas
University of Bologna
Bolonia, ItaliaPublicaciones en colaboración con investigadores/as de University of Bologna (23)
2022
-
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project
Journal of Clinical Oncology, Vol. 364
-
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nature Medicine, Vol. 28, Núm. 2, pp. 325-332
2019
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
2018
-
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: Analysis of the FIRST trial
Leukemia, Vol. 32, Núm. 6, pp. 1404-1413
-
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
Blood Cancer Journal, Vol. 8, Núm. 12
-
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, Núm. 10, pp. e401-e419
2017
-
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study
Leukemia, Vol. 31, Núm. 11, pp. 2443-2448
-
Second primary malignancies in multiple myeloma: An overview and IMWG consensus
Annals of Oncology, Vol. 28, Núm. 2, pp. 228-245
2016
-
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low‐dose dexamethasone versus high‐dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Haematologica, Vol. 101, Núm. 7, pp. 872-878
-
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
Haematologica
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Haematologica, Vol. 100, Núm. 10, pp. 1327-1333
-
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
Haematologica, Vol. 100, Núm. 10, pp. 1334-1339
-
Revised international staging system for multiple myeloma: A report from international myeloma working group
Journal of Clinical Oncology, Vol. 33, Núm. 26, pp. 2863-2869
-
Role of magnetic resonance imaging in the management of patients with multiple myeloma: A consensus statement
Journal of Clinical Oncology, Vol. 33, Núm. 6, pp. 657-664
2014
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362
-
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology, Vol. 15, Núm. 12, pp. e538-e548
2013
-
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: A meta-analysis of phase III randomized, controlled trials
Journal of Clinical Oncology, Vol. 31, Núm. 26, pp. 3279-3287
-
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project
Leukemia, Vol. 27, Núm. 3, pp. 711-717